Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 4/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | RXRA | P19793 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341137 | 0.94 | NPC1 (0.73) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL1599431 | 0.91 | HPGD (0.59) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL29557477 | 0.91 | HPGD (0.59) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL1029034 | 0.88 | SMPD1 (0.75) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL29375753 | 0.88 | SMPD1 (0.75) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL3944668 | 0.87 | MRGPRX4 (0.59) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL11271923 | 0.87 | SMPD1 (0.73) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL4270566 | 0.87 | SMPD1 (0.73) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL9236564 | 0.87 | SMPD1 (0.73) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| Hydrochloric Acid SCHEMBL6586504 | 0.87 | SMPD1 (0.73) | SMPD1HDAC1HDAC8HDAC6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340522-B2 | Pyrazolone-derivatives and their use as PDE-4 inhibitors | TAKEDA GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| CN-103463086-B | Pyrazolone derivatives as PDE4 inhibitors | TAKEDA GMBH (DE) | 2015-10-21 | — | — | CN | disclosed |
| EP-2356103-B1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2015-08-26 | — | — | EP | disclosed |
| US-9090597-B2 | Pyrazolone derivatives as PDE4 inhibitors | TAKEDA GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-8946438-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20140378509-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2014-12-25 | — | — | US | disclosed |
| US-8865745-B2 | Pyrazolone derivatives as PDE4 inhibitors | TAKEDA GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| CN-102369194-B | Pyrazolone derivatives and their use as PD4 inhibitors | NYCOMED GMBH | 2014-08-27 | — | — | CN | disclosed |
| US-20140187539-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| US-8735579-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999032456-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 1999-07-01 | — | — | WO | disclosed |
| EP-0057846-B1 | PYRROLIDINE DERIVATIVE, PROCESS AND INTERMEDIATES FOR ITS PREPARATION AND MEDICAMENTS CONTAINING IT | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1985-06-05 | — | — | EP | disclosed |
| US-4461906-A | IMPROVING INTELLECTUAL CAPACITY | HOFFMANN-LA ROCHE INC. (US) | 1984-07-24 | — | — | US | disclosed |
| EP-0110575-A1 | 1-Aroyl-5-oxo-2-pyrrolidinepropanoic acids and related esters | WARNER-LAMBERT COMPANY (US) | 1984-06-13 | — | — | EP | disclosed |
| US-4452807-A | CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1984-06-05 | — | — | US | disclosed |
| US-4452990-A | TREATMENT OF SENILITY, AMNESIA AND MOTIVATION | WARNER-LAMBERT COMPANY (US) | 1984-06-05 | — | — | US | disclosed |
| EP-0024030-B1 | PYRROLIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-03-30 | — | — | EP | disclosed |
| EP-0057846-A1 | Pyrrolidine derivative, process and intermediates for its preparation and medicaments containing it | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-08-18 | — | — | EP | disclosed |
| EP-0024030-A1 | Pyrrolidine derivatives, processes for their preparation and pharmaceutical compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187539-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | HRH2, HRH1, HRH4 | SMPD1 908/4885HDAC1 531/4885HDAC8 426/4885 |
| US-20140378509-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | SMPD1 118/4885HDAC1 173/4885HDAC8 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.